Sinopia Biosciences Enters into Collaboration with Ono Pharmaceutical for Rare Metabolic Disorders
Wednesday, March 04, 2026
Sinopia Biosciences has announced a target discovery collaboration with Ono Pharmaceutical focused on a group of rare metabolic disorders with significant unmet medical need.
Under the agreement, Sinopia will use its proprietary LEADS® (LEarn And DiScover) drug discovery platform, which is based on metabolomics-driven research, to identify and validate new therapeutic targets. The aim is to address the underlying biochemical dysfunction that contributes to disease progression in genetically defined metabolic conditions.
Targets identified through the collaboration may be advanced by Ono Pharmaceutical towards the development of new treatment options for patients affected by these rare disorders.
The collaboration highlights the application of Sinopia’s platform in uncovering novel therapeutic opportunities in rare metabolic diseases. It also supports the company’s broader strategy of using computational biology and artificial intelligence and machine learning approaches to discover and develop new medicines.
Under the terms of the agreement, Sinopia will receive an upfront payment and research funding, and will be eligible for additional milestone payments in the future. Financial details of the collaboration were not disclosed.
Source: sinopiabio.com
